Anti-IL2 Induction in Liver Transplantation with 93% Rejection-Free Patient and Graft Survival at 18 Months

Ramirez, Carlo B.; Doria, Cataldo; Francesco, Fabrizio di; Iaria, Maurizio; Kang, Yoogoo; Marino, Ignazio R.

doi:10.1016/j.jss.2006.08.025

Cited by 29 publications

(18 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…1 These antibodies permit delayed introduction of CNIs. 40,41 One theoretical concern with their use is elimination of T regulatory cells (which promote tolerance) as these cells also express CD25. 42 …”

Section: Induction Agentsmentioning

confidence: 99%

Current Status of Immunosuppression in Liver Transplantation

Choudhary

Saigal

Shukla

et al. 2013

Journal of Clinical and Experimental Hepatology

View full text Add to dashboard Cite

With advancements in immunosuppressive strategies and availability of better immunosuppressive agents, survival rate following liver transplantation has improved significantly in the recent times. Besides improvements in surgical techniques, the most important factor that has contributed to this better outcome is the progress made in the field of immunosuppression. Over the last several years, the trend has changed to tailored immunosuppression with the aim of achieving optimal graft function while avoiding its undesirable side effects. Induction agents are no longer used routinely and the aim is to provide minimal immunosuppression in the maintenance phase. The present review discusses the various types of immunosuppressive agents, their mechanism of action, clinical utility, advantages and disadvantages, and their side effects in short and long-term. It also discusses about tailoring immunosuppression in presence of various situations such as renal dysfunction, metabolic syndrome, hepatitis C recurrence, cytomegalovirus infections and so on. The issue of chronic kidney disease and the available renal sparing immunosuppressive strategies has been particularly stressed upon. Finally, it discusses about the practical aspects of various immunosuppression regimens including drug monitoring. ( J CLIN EXP HEPATOL 2013;3:150-158)

show abstract

Section: Induction Agentsmentioning

confidence: 99%

Current Status of Immunosuppression in Liver Transplantation

Choudhary

Saigal

Shukla

et al. 2013

Journal of Clinical and Experimental Hepatology

View full text Add to dashboard Cite

show abstract

“…The discovery of new anti-rejection medications, most importantly the first calcineurin inhibitor (CI) cyclosporine A (CsA) has resulted in a significant reduction in rejection rates. During the past two decades, numerous powerful new anti-rejection drugs have been introduced [3] and when using a combination of IL-2RA induction, tacrolimus (TAC) with mycophenolate-mofetil (MMF) and tapered steroids, rejection rates as low as 10-20% during the first year have been reported [4] with 1-year and 5-year patient survival rates of 85-90% and 65%.…”

Section: Introductionmentioning

confidence: 99%

Anti-thymocyte Globulin for the Treatment of Acute Cellular Rejection Following Liver Transplantation

et al. 2010

View full text Add to dashboard Cite

show abstract

“…Anti-IL-2 receptor antibodies are now widely used in liver transplantation as induction agents targeted at reducing the incidence of ACR (2,17,18) or as a calcineurin-inhibitor (19) or steroid-sparing strategy (20,21) to protect renal function in the immediate postoperative period. Comparison of induction therapy (12) between antithymocyte globulin + cyclosporine + steroid + azathioprine and anti-IL-2 receptor antibody + tacrolimus + steroid + azathioprine demonstrated a reduced ACR incidence in the anti-IL-2 receptor antibody group (43% versus 29%; p < 0.01).…”

Section: Resultsmentioning

confidence: 99%